Secondary Immunodeficiencies in the spotlight at IPIC 2025: Kedrion champions innovation and patient care

EQS-News: Kedrion / Key word(s): Miscellaneous/Miscellaneous Secondary Immunodeficiencies in the spotlight at IPIC 2025: Kedrion champions innovation and patient care 06.11.2025 / 14:45 CET/CEST The issuer is solely responsible for the content of this announcement. CASTELVECCHIO PASCOLI, Italy, Nov. 6, 2025 /PRNewswire/ -- Kedrion Biopharma, a biopharmaceutical company specializing in plasma-derived therapies, announces its participation at the International Primary Immunodeficiencies Congress (IPIC) 2025, taking place in Prague, Czech Republic, from November 5–7, 2025. This year, Kedrion hosts a dedicated Satellite Symposium, "Secondary Immunodeficiencies in Hematologic Malignancies: A Growing Area of Interest," shining a spotlight on one of the most pressing and evolving topics in Immunology.

The Symposium, scheduled for today, opens with an introduction by Dr. Fabian Peissker, Medical Affairs at Kedrion, and features leading experts: Prof. Hermann Wolf (Sigmund Freud University, Vienna, Austria) and Dr. Federica Pulvirenti (Policlinico Umberto I, Rome, Italy), who will address the challenges and advances in diagnosing and managing Secondary Immunodeficiencies (SIDs) in patients with hematologic malignancies. The session includes real-world clinical experiences and an interactive Q&A, offering practical insights for clinicians and researchers.

Secondary Immunodeficiencies, particularly in patients with B-cell hematological malignancies, represent a significant clinical challenge due to their complex pathogenesis and the increased risk of life-threatening infections. Advances in cancer therapies have improved survival, but complications, in particular Hypogammaglobulinemia and infections, can compromise treatment outcomes and patient quality of life. Early diagnosis and appropriate management, including Immunoglobulin replacement therapy, are critical to improving patient care and reducing infection-related complications.